JP5615271B2 - ウイルス精製法 - Google Patents

ウイルス精製法 Download PDF

Info

Publication number
JP5615271B2
JP5615271B2 JP2011514119A JP2011514119A JP5615271B2 JP 5615271 B2 JP5615271 B2 JP 5615271B2 JP 2011514119 A JP2011514119 A JP 2011514119A JP 2011514119 A JP2011514119 A JP 2011514119A JP 5615271 B2 JP5615271 B2 JP 5615271B2
Authority
JP
Japan
Prior art keywords
retroviral vector
vector
formulation
retroviral
ultrafiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011514119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011524887A (ja
JP2011524887A5 (enExample
Inventor
トルラン，リチャード
バックリー，ロバート
ラドクリフ，ピッパ
ミスキン，ジェームズ
ミトロファヌース，キリ
Original Assignee
オックスフォード バイオメディカ（ユーケー）リミテッド
オックスフォード バイオメディカ（ユーケー）リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40940324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5615271(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by オックスフォード バイオメディカ（ユーケー）リミテッド, オックスフォード バイオメディカ（ユーケー）リミテッド filed Critical オックスフォード バイオメディカ（ユーケー）リミテッド
Publication of JP2011524887A publication Critical patent/JP2011524887A/ja
Publication of JP2011524887A5 publication Critical patent/JP2011524887A5/ja
Application granted granted Critical
Publication of JP5615271B2 publication Critical patent/JP5615271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Manufacturing & Machinery (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011514119A 2008-06-18 2009-06-18 ウイルス精製法 Active JP5615271B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7368508P 2008-06-18 2008-06-18
US61/073,685 2008-06-18
PCT/GB2009/001527 WO2009153563A1 (en) 2008-06-18 2009-06-18 Virus purification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014142447A Division JP6002720B2 (ja) 2008-06-18 2014-07-10 ウイルス精製法

Publications (3)

Publication Number Publication Date
JP2011524887A JP2011524887A (ja) 2011-09-08
JP2011524887A5 JP2011524887A5 (enExample) 2012-07-19
JP5615271B2 true JP5615271B2 (ja) 2014-10-29

Family

ID=40940324

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011514119A Active JP5615271B2 (ja) 2008-06-18 2009-06-18 ウイルス精製法
JP2014142447A Expired - Fee Related JP6002720B2 (ja) 2008-06-18 2014-07-10 ウイルス精製法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014142447A Expired - Fee Related JP6002720B2 (ja) 2008-06-18 2014-07-10 ウイルス精製法

Country Status (8)

Country Link
US (1) US9169491B2 (enExample)
EP (2) EP2307551B1 (enExample)
JP (2) JP5615271B2 (enExample)
CN (2) CN102124115B (enExample)
DK (2) DK3192874T3 (enExample)
ES (2) ES2762864T3 (enExample)
PL (2) PL2307551T3 (enExample)
WO (1) WO2009153563A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2680915T3 (es) 2010-01-28 2018-09-11 The Children's Hospital Of Philadelphia Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica
EP2575894B1 (en) 2010-05-28 2015-02-25 Oxford Biomedica (UK) Ltd Delivery of lentiviral vectors to the brain
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
US20140315294A1 (en) 2011-11-24 2014-10-23 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
PT2790737T (pt) 2011-12-12 2019-02-28 Childrens Hospital Philadelphia Sistema de produção de vetores lentivirais a grande escala comercial e vetores produzidos pelo mesmo
ES2765880T3 (es) 2012-01-09 2020-06-11 Sanofi Pasteur Biologics Llc Purificación del virus del herpes
WO2013177172A2 (en) 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
DK3889173T5 (da) 2013-02-15 2024-08-05 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
BR112015022292A2 (pt) * 2013-03-15 2017-07-18 Childrens Hospital Philadelphia processo de fabricação escalonável para produzir vetores lentivirais recombinantes em um sistema de cultura celular em suspensão sem soro
FR3010720B1 (fr) 2013-09-16 2017-08-11 Genethon Procede de production de virus enveloppes
FR3014901B1 (fr) * 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
CN104371982A (zh) * 2014-10-21 2015-02-25 武汉维诺赛生物技术有限公司 一种慢病毒的纯化方法
AU2015341481C1 (en) 2014-11-03 2021-09-16 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T cell receptors directed against Bob1 and uses thereof
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
WO2016142783A2 (en) 2015-03-10 2016-09-15 Leiden University Medical Center T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
EP3380620B1 (en) 2015-11-23 2024-07-03 Novartis AG Optimized lentiviral transfer vectors and uses thereof
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
CN107043784A (zh) * 2016-02-05 2017-08-15 上海吉凯基因化学技术有限公司 一种慢病毒载体的制备方法
JP2019519250A (ja) 2016-05-10 2019-07-11 ユナイテッド ステイツ ガバメント アズ リプレゼンテッド バイ ザ デパートメント オブ ベテランズ アフェアーズＵｎｉｔｅｄ Ｓｔａｔｅｓ Ｇｏｖｅｒｎｍｅｎｔ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｖｅｔｅｒａｎｓ Ａｆｆａｉｒｓ Ｈｉｖ−１感染と複製に必須な遺伝子を切断するｃｒｉｓｐｒ／ｃａｓの構築物のレンチウィルスによる送達
GB201614050D0 (en) * 2016-08-17 2016-09-28 Glaxosmithkline Ip Dev Ltd Method for purifying viral vectors
MA50877A (fr) 2017-11-21 2020-09-30 Bayer Healthcare Llc Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
CA3084633A1 (en) 2017-12-21 2019-06-27 Crispr Therapeutics Ag Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
AU2018393050A1 (en) 2017-12-21 2020-06-18 Bayer Healthcare Llc Materials and methods for treatment of Usher Syndrome Type 2A
FI3633040T3 (fi) 2017-12-22 2023-08-03 Oxford Biomedica Ltd Retrovirusvektori
RU2020132890A (ru) * 2018-04-05 2022-05-06 Оксфорд Юниверсити Инновейшн Лимитед Композиции и способы лечения макулярной дистрофии
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
EP3806629A4 (en) 2018-06-12 2022-05-04 Kentucky Bioprocessing, Inc. VIRUS AND ANTIGEN CLEANING AND CONJUGATION
JP2021533831A (ja) * 2018-08-16 2021-12-09 スペースクラフト セブン リミテッド ライアビリティ カンパニー ウイルスベクターのための生成方法
EP3937985A1 (en) 2019-03-10 2022-01-19 Sio Gene Therapies Inc. Gene therapy compositions and methods for treating parkinson's disease
WO2020214676A1 (en) * 2019-04-15 2020-10-22 Children's Hospital Medical Center Viral vector manufacturing methods
US12037599B2 (en) 2019-08-23 2024-07-16 Lonza Walkersville, Inc. Methods and constructs for production of lentiviral vector
CN115279896A (zh) 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 慢病毒载体配制品
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
EP4103723A1 (en) 2020-02-13 2022-12-21 Oxford BioMedica (UK) Limited Production of lentiviral vectors
EP4118217A1 (en) 2020-03-13 2023-01-18 Oxford BioMedica (UK) Limited Lentiviral vectors
AU2021264465A1 (en) 2020-04-27 2022-12-15 University Of Iowa Research Foundation Compositions and methods for the treatment of cystic fibrosis
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
CA3188923A1 (en) * 2020-08-13 2022-02-17 Michael Sean BURNHAM Methods for producing clinical-grade lentiviral vector
CN112226418B (zh) * 2020-09-25 2022-07-08 阜外华中心血管病医院 重组腺相关病毒纯化方法
JP2023544184A (ja) * 2020-10-02 2023-10-20 ジェネラックス・コーポレイション 接着細胞からのウイルスのバイオリアクター生成
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
CN112899242A (zh) * 2021-02-03 2021-06-04 苏州博腾生物制药有限公司 慢病毒纯化工艺
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
EP4424705A1 (en) 2021-10-29 2024-09-04 Agc Inc. Composition for cell addition
EP4431600A1 (en) 2021-11-12 2024-09-18 Agc Inc. Virus purification method
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
CN116240241A (zh) * 2022-12-30 2023-06-09 上海本导基因技术有限公司 重组慢病毒载体的纯化制备方法
EP4658797A2 (en) * 2023-02-01 2025-12-10 Interius Biotherapeutics, Inc. Processes for the filtration or purification of viral particles
WO2024259299A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Compositions and methods for identification of vhh antibodies that bind a target antigen

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78703A (en) 1985-05-10 1993-02-21 Benzon Alfred Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
WO1992014829A1 (en) 1991-02-19 1992-09-03 The Regents Of The University Of California Viral particles having altered host range
CA2181066A1 (en) * 1994-01-12 1995-07-20 Hitoshi Kotani Purification of retroviral vectors
EP0751988B1 (en) 1994-03-22 2000-02-09 The Immune Response Corporation Highly efficient production and isolation of viral particles
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2263154A1 (en) 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
CN1195863C (zh) 1996-10-17 2005-04-06 牛津生物医学（英国）有限公司 逆转录病毒载体
EP1707631A3 (en) * 1996-11-20 2006-12-27 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB2351290A (en) 1998-05-22 2000-12-27 Oxford Biomedica Ltd Retroviral delivery sytem
GB9904905D0 (en) 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (enExample) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
AU2003220531B2 (en) * 2002-03-29 2007-11-01 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
ES2285120T3 (es) 2002-05-14 2007-11-16 MERCK & CO., INC. Procedimientos de purificacion de adenovirus.
AU2003260769A1 (en) 2002-09-03 2004-03-29 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
US20050123514A1 (en) * 2003-05-05 2005-06-09 Brian Davis Increased transduction using ABC transporter substrates and/or inhibitors
SE0302509D0 (sv) 2003-09-19 2003-09-19 Amersham Biosciences Ab Matrix for separation of polyethers and method of separation
WO2005039643A2 (en) * 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of parkinson's disease
CN1922308A (zh) * 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
EP2007883B1 (en) 2006-04-20 2011-12-28 Wyeth LLC Purification processes for isolating purified vesicular stomatitis virus from cell culture
WO2008065430A2 (en) * 2006-12-01 2008-06-05 Oxford Biomedica (Uk) Limited Promoter construct
CA2678774A1 (en) 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
PL2209814T3 (pl) * 2007-11-13 2017-08-31 Bio-Technology General (Israel) Ltd. Proces sterylizacji przez filtrację z rozcieńczaniem dla lepkosprężystych biopolimerów

Also Published As

Publication number Publication date
US20090325284A1 (en) 2009-12-31
WO2009153563A1 (en) 2009-12-23
JP6002720B2 (ja) 2016-10-05
JP2011524887A (ja) 2011-09-08
ES2762864T3 (es) 2020-05-26
CN102124115B (zh) 2020-03-03
JP2014237661A (ja) 2014-12-18
EP2307551A1 (en) 2011-04-13
EP3192874B1 (en) 2019-10-16
PL3192874T3 (pl) 2020-06-29
CN103993040A (zh) 2014-08-20
CN103993040B (zh) 2018-02-13
EP3192874A1 (en) 2017-07-19
CN102124115A (zh) 2011-07-13
PL2307551T3 (pl) 2017-07-31
DK2307551T3 (en) 2017-03-20
EP2307551B1 (en) 2016-12-14
US9169491B2 (en) 2015-10-27
DK3192874T3 (da) 2019-12-16
ES2618851T3 (es) 2017-06-22

Similar Documents

Publication Publication Date Title
JP6002720B2 (ja) ウイルス精製法
US20230118587A1 (en) Lentiviral Vectors
US10273502B2 (en) Virus purification
JP7759318B2 (ja) 産生系
CN115667533A (zh) 慢病毒载体的生产
JP2023534924A (ja) ウイルスフソソームを産生するための方法及び組成物
US8278284B2 (en) Therapeutic agents for diseases associated with apoptotic degeneration in ocular tissue cells that use SIV-PEDF vectors
US20250043308A1 (en) Purification Method of Viral Vectors
WO2024038266A1 (en) Envelope proteins
HK40101430A (en) Preparation of a solution of polymer/nucleic acid complexes
HK40102339A (en) Preparation of a solution of polymer/nucleic acid complexes
JP2025188163A (ja) ウイルスフソソームを産生するための方法及び組成物
IL302632A (en) Preparation of a solution of polymer/nucleic acid complexes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140710

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140812

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140909

R150 Certificate of patent or registration of utility model

Ref document number: 5615271

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250